Literature DB >> 4016673

Primary lymphomas of the nasal cavity and paranasal sinuses.

K T Robbins, L M Fuller, M Vlasak, B Osborne, B S Jing, W S Velasquez, J A Sullivan.   

Abstract

Extranodal lymphomas which present in the nasal cavity and/or the paranasal sinuses are rare. Thirty-eight patients with disease that was clinically limited to the head and neck (Ann Arbor Stages IE-IIE) were admitted between 1947 and 1983. Twenty-eight patients were treated with radiotherapy alone and 10 received combination chemotherapy in addition. The overall 5-year survival figure was 56%. The corresponding result for Stage IE was 67%. No patient with Stage IIE disease survived 5 years. Extent of the extranodal disease also influenced results for Stage IE patients who were treated with radiotherapy only. When the extranodal disease was staged using the American Joint Committee TNM system, the 5-year disease-free survival for T1 and T2 patients was 78% as compared with 19% for patients with T3 and T4 disease. The addition of combination chemotherapy improved results for patients with T3 and T4 lesions.

Entities:  

Mesh:

Year:  1985        PMID: 4016673     DOI: 10.1002/1097-0142(19850815)56:4<814::aid-cncr2820560419>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Sight-threatening optic neuropathy is associated with paranasal lymphoma.

Authors:  Takahiko Hayashi; Ken Watanabe; Yukio Tsuura; Gengo Tsuji; Shingo Koyama; Jun Yoshigi; Naoko Hirata; Shin Yamane; Yasuhito Iizima; Shigeo Toyota; Satoshi Takeuchi
Journal:  Clin Ophthalmol       Date:  2010-03-24

2.  Sinonasal non-Hodgkin's lymphomas and Wegener's granulomatosis: a clinicopathological study.

Authors:  L A Noorduyn; R Torenbeek; P van der Valk; P B Drosten; G B Snow; A J Balm; G J Ossenkoppele; C J Meyer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Malignant lymphomas of the nasal cavity and paranasal sinuses.

Authors:  C Fellbaum; M L Hansmann; K Lennert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma.

Authors:  Adrien Chauchet; Anne-Sophie Michallet; Françoise Berger; Isabelle Bedgedjian; Eric Deconinck; Catherine Sebban; Daciana Antal; Hubert Orfeuvre; Bernadette Corront; Tony Petrella; Maya Hacini; Marie Bouteloup; Gilles Salles; Bertrand Coiffier
Journal:  J Hematol Oncol       Date:  2012-06-08       Impact factor: 17.388

5.  Extranodal natural-killer/t-cell lymphoma, nasal type.

Authors:  Harinder Gill; Raymond H S Liang; Eric Tse
Journal:  Adv Hematol       Date:  2010-12-30

6.  A TNM Staging System for Nasal NK/T-Cell Lymphoma.

Authors:  Zheng Yan; Hui-qiang Huang; Xiao-xiao Wang; Yan Gao; Yu-jing Zhang; Bing Bai; Wei Zhao; Wen-qi Jiang; Zhi-ming Li; Zhong-jun Xia; Su-xia Lin; Chuan-miao Xie
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

Review 7.  Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis.

Authors:  Margarida Lima
Journal:  Orphanet J Rare Dis       Date:  2013-07-01       Impact factor: 4.123

8.  Clinical impact of lymphatic spread in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Yong Oh; Sung-Nam Lim; Won-Sik Lee; Sang-Min Lee; Do-Young Kim
Journal:  Blood Res       Date:  2021-06-30

Review 9.  Primary Thyroid Extranasal NK/T-Cell Lymphoma Associated With Good Outcome: A Case Report and Literature Review: A Care-Compliant Article.

Authors:  Jun-He Li; Hong-Hong He; Yuan Cheng; Wen-Jing He
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma.

Authors:  Xudong Zhang; Weiguo Ji; Ruixia Huang; Lifeng Li; Xinhua Wang; Ling Li; Xiaorui Fu; Zhenchang Sun; Zhaoming Li; Qingjiang Chen; Mingzhi Zhang
Journal:  Oncotarget       Date:  2016-08-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.